Kathryn Taylor1, Nadia M Chu2,3, Xiaomeng Chen2, Zhan Shi2, Eileen Rosello2, Sneha Kunwar2, Paul Butz2, Silas P Norman4, Deidra C Crews5, Keiko I Greenberg6, Aarti Mathur2, Dorry L Segev2,3, Tariq Shafi5,7, Mara A McAdams-DeMarco8,3. 1. Johns Hopkins University School of Nursing, Baltimore, Maryland. 2. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 4. Department of Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan. 5. Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 6. Department of Medicine, Division of Nephrology and Hypertension, MedStar Georgetown University Hospital, Washington, DC. 7. Department of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, Mississippi. 8. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland mara@jhu.edu.
Abstract
BACKGROUND AND OBJECTIVES: Patients with kidney failure report a high symptom burden, which likely increases while on dialysis due to physical and mental stressors and decreases after kidney transplantation due to restoration of kidney function. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We leveraged a two-center prospective study of 1298 kidney transplant candidates and 521 recipients (May 2014 to March 2020). Symptom scores (0-100) at evaluation and admission for transplantation were calculated using the Kidney Disease Quality of Life Short-Form Survey, where lower scores represent greater burden, and burden was categorized as very high: 0.0-71.0; high: 71.1-81.0; medium: 81.1-91.0; and low: 91.1-100.0. We estimated adjusted waitlist mortality risk (competing risks regression), change in symptoms between evaluation and transplantation (n=190), and post-transplantation symptom score trajectories (mixed effects models). RESULTS: At evaluation, candidates reported being moderately to extremely bothered by fatigue (32%), xeroderma (27%), muscle soreness (26%), and pruritus (25%); 16% reported high and 21% reported very high symptom burden. Candidates with very high symptom burden were at greater waitlist mortality risk (adjusted subdistribution hazard ratio, 1.67; 95% confidence interval, 1.06 to 2.62). By transplantation, 34% experienced an increased symptom burden, whereas 42% remained unchanged. The estimated overall symptom score was 82.3 points at transplantation and 90.6 points at 3 months (10% improvement); the score increased 2.75 points per month (95% confidence interval, 2.38 to 3.13) from 0 to 3 months, and plateaued (-0.06 points per month; 95% confidence interval, -0.30 to 0.18) from 3 to 12 months post-transplantation. There were early (first 3 months) improvements in nine of 11 symptoms; pruritus (23% improvement) and fatigue (21% improvement) had the greatest improvements. CONCLUSIONS: Among candidates, very high symptom burden was associated with waitlist mortality, but for those surviving and undergoing kidney transplantation, symptoms improved.
BACKGROUND AND OBJECTIVES: Patients with kidney failure report a high symptom burden, which likely increases while on dialysis due to physical and mental stressors and decreases after kidney transplantation due to restoration of kidney function. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We leveraged a two-center prospective study of 1298 kidney transplant candidates and 521 recipients (May 2014 to March 2020). Symptom scores (0-100) at evaluation and admission for transplantation were calculated using the Kidney Disease Quality of Life Short-Form Survey, where lower scores represent greater burden, and burden was categorized as very high: 0.0-71.0; high: 71.1-81.0; medium: 81.1-91.0; and low: 91.1-100.0. We estimated adjusted waitlist mortality risk (competing risks regression), change in symptoms between evaluation and transplantation (n=190), and post-transplantation symptom score trajectories (mixed effects models). RESULTS: At evaluation, candidates reported being moderately to extremely bothered by fatigue (32%), xeroderma (27%), muscle soreness (26%), and pruritus (25%); 16% reported high and 21% reported very high symptom burden. Candidates with very high symptom burden were at greater waitlist mortality risk (adjusted subdistribution hazard ratio, 1.67; 95% confidence interval, 1.06 to 2.62). By transplantation, 34% experienced an increased symptom burden, whereas 42% remained unchanged. The estimated overall symptom score was 82.3 points at transplantation and 90.6 points at 3 months (10% improvement); the score increased 2.75 points per month (95% confidence interval, 2.38 to 3.13) from 0 to 3 months, and plateaued (-0.06 points per month; 95% confidence interval, -0.30 to 0.18) from 3 to 12 months post-transplantation. There were early (first 3 months) improvements in nine of 11 symptoms; pruritus (23% improvement) and fatigue (21% improvement) had the greatest improvements. CONCLUSIONS: Among candidates, very high symptom burden was associated with waitlist mortality, but for those surviving and undergoing kidney transplantation, symptoms improved.
Authors: Jeffrey Perl; Laura M Dember; Joanne M Bargman; Teri Browne; David M Charytan; Jennifer E Flythe; LaTonya J Hickson; Adriana M Hung; Michel Jadoul; Timmy Chang Lee; Klemens B Meyer; Hamid Moradi; Tariq Shafi; Isaac Teitelbaum; Leslie P Wong; Christopher T Chan Journal: Clin J Am Soc Nephrol Date: 2017-03-17 Impact factor: 8.237
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: H Ozcan; A Yucel; U Z Avşar; E Cankaya; N Yucel; H Gözübüyük; F Eren; M Keles; B Aydınlı Journal: Transplant Proc Date: 2015-06 Impact factor: 1.066
Authors: Mara A McAdams-DeMarco; Israel O Olorundare; Hao Ying; Fatima Warsame; Christine E Haugen; Rasheeda Hall; Jacqueline M Garonzik-Wang; Niraj M Desai; Jeremy D Walston; Silas P Norman; Dorry L Segev Journal: Transplantation Date: 2018-02 Impact factor: 4.939
Authors: Adrian R Levy; Shan Xing; Steven M Brunelli; Kerry Cooper; Fredric O Finkelstein; Michael J Germain; Miriam Kimel; Robert W Platt; Vasily Belozeroff Journal: Am J Kidney Dis Date: 2019-10-16 Impact factor: 8.860
Authors: Eugene P Rhee; Eliseo Guallar; Seungyoung Hwang; Noori Kim; Marcello Tonelli; Sharon M Moe; Jonathan Himmelfarb; Ravi I Thadhani; Neil R Powe; Tariq Shafi Journal: Kidney360 Date: 2020-02
Authors: Naoka Murakami; Nathan D Baggett; Margaret L Schwarze; Keren Ladin; Andrew M Courtwright; Hilary J Goldberg; Eric P Nolley; Nelia Jain; Michael Landzberg; Kirsten Wentlandt; Jennifer C Lai; Myrick C Shinall; Nneka N Ufere; Christopher A Jones; Joshua R Lakin Journal: J Palliat Med Date: 2022-03-11 Impact factor: 2.947